Ultragenyx Pharmaceutical Inc. (RARE) Stock Rating Upgraded by Zacks Investment Research
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.
According to Zacks, “Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company’s product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. “
Other analysts also recently issued research reports about the company. Jefferies Group LLC restated a “hold” rating and set a $68.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday. SunTrust Banks, Inc. boosted their price objective on Ultragenyx Pharmaceutical from $100.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, April 19th. Wedbush downgraded Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $80.00 to $75.00 in a report on Wednesday, April 19th. Piper Jaffray Companies downgraded Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $96.00 to $70.00 in a report on Wednesday, March 22nd. Finally, HC Wainwright downgraded Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $88.00 to $72.00 in a report on Wednesday, April 19th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $85.71.
Ultragenyx Pharmaceutical (NASDAQ RARE) opened at 66.29 on Tuesday. The stock’s market cap is $2.80 billion. The stock has a 50 day moving average of $59.37 and a 200-day moving average of $68.56. Ultragenyx Pharmaceutical has a one year low of $49.97 and a one year high of $91.35.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.71) by $0.08. During the same period last year, the company posted ($1.35) EPS. Analysts anticipate that Ultragenyx Pharmaceutical will post ($7.02) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Ultragenyx Pharmaceutical Inc. (RARE) Stock Rating Upgraded by Zacks Investment Research” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/07/18/ultragenyx-pharmaceutical-inc-rare-stock-rating-upgraded-by-zacks-investment-research.html.
In related news, VP Theodore Alan Huizenga sold 480 shares of the stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $57.46, for a total value of $27,580.80. Following the transaction, the vice president now owns 9,366 shares in the company, valued at $538,170.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 9.20% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in Ultragenyx Pharmaceutical by 102,249.1% in the first quarter. BlackRock Inc. now owns 3,166,680 shares of the biopharmaceutical company’s stock worth $214,637,000 after buying an additional 3,163,586 shares in the last quarter. Norges Bank purchased a new position in Ultragenyx Pharmaceutical during the fourth quarter worth approximately $36,717,000. FMR LLC increased its position in Ultragenyx Pharmaceutical by 3.9% in the first quarter. FMR LLC now owns 6,110,627 shares of the biopharmaceutical company’s stock worth $414,178,000 after buying an additional 227,802 shares in the last quarter. Vanguard Group Inc. increased its position in Ultragenyx Pharmaceutical by 5.7% in the first quarter. Vanguard Group Inc. now owns 2,994,938 shares of the biopharmaceutical company’s stock worth $202,997,000 after buying an additional 161,622 shares in the last quarter. Finally, Bank of Montreal Can increased its position in Ultragenyx Pharmaceutical by 8,939.4% in the first quarter. Bank of Montreal Can now owns 101,603 shares of the biopharmaceutical company’s stock worth $6,887,000 after buying an additional 100,479 shares in the last quarter. Hedge funds and other institutional investors own 95.25% of the company’s stock.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.